A strategy to reduce cardiovascular disease by more than 80%

被引:1116
作者
Wald, NJ [1 ]
Law, MR [1 ]
机构
[1] Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2003年 / 326卷 / 7404期
关键词
D O I
10.1136/bmj.326.7404.1419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretreatment levels. Design We quantified the efficacy and adverse effects of the proposed formulation from published meta-analyses of randomised trials and cohort studies and a meta-analysis of 15 trials of low dose (50-125 mg/day) aspirin. Outcome measures Proportional reduction in ischaemic heart disease (IHD) events and strokes; life years gained; and prevalence of adverse effects. Results The formulation which met our objectives was: a statin (for example, atorvastatin (daily dose 10 mg) or simvastatin (40 mg); three blood pressure lowering drugs (for example, a thiazide, a P blocker, and an angiotensin converting enzyme inhibitor), each at half standard dose; folic acid (0.8 mg); and aspirin (75 mg). We estimate that the combination (which we call the Polypill) reduces IHD events by 88% (95% confidence interval 84% to 91%) and stroke by 80% (71% to 87%). One third of people taking this pill from age 55 would benefit, gaining on average about I I years of life free from an IHD event or stroke. Summing the adverse effects of the components observed in randomised trials shows that the Polypill would cause symptoms in 8-15% of people (depending on the precise formulation). Conclusion The Polypill strategy could largely prevent heart attacks and stroke if taken by everyone aged 55 and older and everyone with existing cardiovascular disease. It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than an), other single intervention.
引用
收藏
页码:1419 / 1423
页数:5
相关论文
共 25 条
  • [1] [Anonymous], 1988, LANCET, V2, P349
  • [2] [Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
  • [3] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [4] Brattström L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894
  • [5] *BRIT MED ASS, 2002, 44 BMA RPS
  • [6] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [7] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [8] Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
    Law, MR
    Wald, NJ
    Morris, JK
    Jordan, RE
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7404): : 1427 - 1431
  • [9] BY HOW MUCH AND HOW QUICKLY DOES REDUCTION IN SERUM-CHOLESTEROL CONCENTRATION LOWER RISK OF ISCHEMIC-HEART-DISEASE
    LAW, MR
    WALD, NJ
    THOMPSON, SG
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6925): : 367 - 373
  • [10] The underlying risk of death after myocardial infarction in the absence of treatment
    Law, MR
    Watt, HC
    Wald, NJ
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (21) : 2405 - 2410